Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 trial designed to evaluate safety and tolerability of chemotherapy in
combination with inotuzumab ozogamicin, an investigational product, in adults with
CD22-positive non-Hodgkin's lymphoma. The trial will involve two arms. In one arm, subjects
will receive chemotherapy regimen R-CVP (rituximab, cyclophosphamide, vincristine and
prednisone). In the other arm, subjects will receive R-GDP (rituximab, gemcitabine,
cisplatinum and dexamethasone). Subjects in both arms will also receive inotuzumab
ozogamicin.